中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2013年
6期
606-608
,共3页
血管性痴呆%尼莫地平%丁苯酞
血管性癡呆%尼莫地平%丁苯酞
혈관성치태%니막지평%정분태
Vascular dementia%Nimodipine%Butyiphthalide
目的 观察丁苯酞软胶囊联合尼莫地平治疗血管性痴呆的效果和安全性.方法 80例患者随机分为治疗组40例和对照组40例.对照组给予尼莫地平30 mg口服,3次/d；治疗组在此基础上加用丁苯酞0.2g口服,3次/d.疗程12周.分别于治疗前和治疗后进行认知功能测定,采用简易精神状态检查表(MMSE)、临床痴呆程度量表(CDR)和日常生活能力量表(ADL)作为评价指标,并监测治疗后的不良反应.结果 对照组治疗前MMSE评分(16.28±2.11)分较治疗后(19.43 ±2.04)分比较,差异有统计学意义(t=2.34,P＜0.05),对照组治疗前CDR评分(1.75±0.31)分较治疗后(1.21±0.50)分比较,差异有统计学意义(t=1.54,P＜0.05),对照组治疗前ADL评分(46.75±5.31)分较治疗后(41.22±4.80)分比较,差异有统计学意义(t=5.24,P＜0.05)；治疗组治疗前MMSE评分(16.54±1.98)分、CDR评分(1.78±0.25)分、ADL评分(47.45±5.22)分较治疗后[MMSE评分(23.17±1.89)分、CDR评分(1.06±0.11)分、ADL评分(40.11±5.10)分]比较,差异均有统计学意义(t值分别为2.42、1.67、6.73,P均＜0.05).且治疗后治疗组MMSE、CDR、ADL评分较对照组均明显改善(t值分别为1.85、1.84、5.91,P均＜0.05).两组均未发现明显的不良反应.结论 丁苯酞软胶囊联合尼莫地平治疗血管性痴呆效果优于单用尼莫地平,且安全性良好.
目的 觀察丁苯酞軟膠囊聯閤尼莫地平治療血管性癡呆的效果和安全性.方法 80例患者隨機分為治療組40例和對照組40例.對照組給予尼莫地平30 mg口服,3次/d；治療組在此基礎上加用丁苯酞0.2g口服,3次/d.療程12週.分彆于治療前和治療後進行認知功能測定,採用簡易精神狀態檢查錶(MMSE)、臨床癡呆程度量錶(CDR)和日常生活能力量錶(ADL)作為評價指標,併鑑測治療後的不良反應.結果 對照組治療前MMSE評分(16.28±2.11)分較治療後(19.43 ±2.04)分比較,差異有統計學意義(t=2.34,P＜0.05),對照組治療前CDR評分(1.75±0.31)分較治療後(1.21±0.50)分比較,差異有統計學意義(t=1.54,P＜0.05),對照組治療前ADL評分(46.75±5.31)分較治療後(41.22±4.80)分比較,差異有統計學意義(t=5.24,P＜0.05)；治療組治療前MMSE評分(16.54±1.98)分、CDR評分(1.78±0.25)分、ADL評分(47.45±5.22)分較治療後[MMSE評分(23.17±1.89)分、CDR評分(1.06±0.11)分、ADL評分(40.11±5.10)分]比較,差異均有統計學意義(t值分彆為2.42、1.67、6.73,P均＜0.05).且治療後治療組MMSE、CDR、ADL評分較對照組均明顯改善(t值分彆為1.85、1.84、5.91,P均＜0.05).兩組均未髮現明顯的不良反應.結論 丁苯酞軟膠囊聯閤尼莫地平治療血管性癡呆效果優于單用尼莫地平,且安全性良好.
목적 관찰정분태연효낭연합니막지평치료혈관성치태적효과화안전성.방법 80례환자수궤분위치료조40례화대조조40례.대조조급여니막지평30 mg구복,3차/d；치료조재차기출상가용정분태0.2g구복,3차/d.료정12주.분별우치료전화치료후진행인지공능측정,채용간역정신상태검사표(MMSE)、림상치태정도량표(CDR)화일상생활능역량표(ADL)작위평개지표,병감측치료후적불량반응.결과 대조조치료전MMSE평분(16.28±2.11)분교치료후(19.43 ±2.04)분비교,차이유통계학의의(t=2.34,P＜0.05),대조조치료전CDR평분(1.75±0.31)분교치료후(1.21±0.50)분비교,차이유통계학의의(t=1.54,P＜0.05),대조조치료전ADL평분(46.75±5.31)분교치료후(41.22±4.80)분비교,차이유통계학의의(t=5.24,P＜0.05)；치료조치료전MMSE평분(16.54±1.98)분、CDR평분(1.78±0.25)분、ADL평분(47.45±5.22)분교치료후[MMSE평분(23.17±1.89)분、CDR평분(1.06±0.11)분、ADL평분(40.11±5.10)분]비교,차이균유통계학의의(t치분별위2.42、1.67、6.73,P균＜0.05).차치료후치료조MMSE、CDR、ADL평분교대조조균명현개선(t치분별위1.85、1.84、5.91,P균＜0.05).량조균미발현명현적불량반응.결론 정분태연효낭연합니막지평치료혈관성치태효과우우단용니막지평,차안전성량호.
Objective To observe the efficacy and safety of butyiphthalide and nimodipine in the treatment of vascular dementia (VAD).Methods Eighty cases with VAD were randomly divided into the treatment group (40 cases) and the control group (40 cases).The control group were given 30 mg nimodipine for three times a day ;The treatment group was given additionally three times a day of 0.2 g butyiphthalide for 12 consecutive weeks.The Mini-Mental State Examination (MMSE),Clinical Dementia Rating (CDR),and Activities of Daily Living (ADL) scores were used for the assessment of cognitive function.The assessments were done before and after treatment.The adverse effects were also recorded.Results In the treatment and the control groups,the MMSE,CDR and ADL scores (MMSE:23.17 ± 1.89,19.43 ± 2.04; CDR:1.06 ± 0.11,1.21 ±0.50;ADL:40.11 ±5.10,41.22 ±4.80) after treatment were significantly improved than those (MMSE:16.54 ± 1.98,16.28 ± 2.11 ; CDR:1.78 ± 0.25,1.75 ± 0.31 ; ADL:47.45 ± 5.22,46.75 ± 5.31) (MMSE:t =2.42,P ＜0.05,t =2.34,P ＜0.05 ;CDR:t =1.67,P ＜ 0.05,t =1.54,P ＜0.05 ;ADL:t =6.73,P ＜0.05,t =5.24,P ＜ 0.05) before treatment.After 12 weeks of treatment,the MMSE,CDR and ADL scores in the butyiphthalide group were significantly improved than that in the control group (t =1.85,1.84,5.91,respectively; P ＜ 0.05).No serious adverse events were recorded during the treatment.Conclusion Butyiphthalide and nimodipine can prominently improve,better than nimodipine alone,the cognitive function of patients with vascular dementia.Moreover,its security and tolerability are good.
